Noriaki Maruyama - Publications

Limited Utility of Serum Hepcidin as a Marker for Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients: An Analysis From the INFINITY Cohort.

Journal: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

Published: February 22, 2025

The prognostic value of serum hepcidin-25 in predicting cardiovascular events among maintenance hemodialysis patients: insights from the INFINITY cohort.

Journal: Clinical and experimental nephrology

Published: January 10, 2025

Correlation between Aortic Calcification Score and Biochemical Parameters in Hemodialysis Patients.

Journal: Contributions to nephrology

Published: April 17, 2019

Targets and Therapeutics for Glycemic Control in Diabetes Patients on Hemodialysis.

Journal: Contributions to nephrology

Published: July 25, 2018

Efficacy of L-carnitine supplementation for improving lean body mass and physical function in patients on hemodialysis: a randomized controlled trial.

Journal: European journal of clinical nutrition

Published: July 09, 2018

Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.

Journal: Diabetes & vascular disease research

Published: June 21, 2018

Effect of Sucroferric Oxyhydroxide on Fibroblast Growth Factor 23 Levels in Hemodialysis Patients.

Journal: Nephron

Published: April 30, 2018

Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoietin Responsiveness in Hemodialysis Patients.

Journal: American journal of nephrology

Published: March 14, 2018

Glycated Albumin versus Glycated Hemoglobin as a Glycemic Indicator in Diabetic Patients on Peritoneal Dialysis.

Journal: International journal of molecular sciences

Published: March 16, 2016

Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage.

Journal: International journal of molecular sciences

Published: October 07, 2015

A Trial of Pitavastatin Versus Rosuvastatin for Dyslipidemia in Chronic Kidney Disease.

Journal: Journal of atherosclerosis and thrombosis

Published: July 10, 2015

Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease.

Journal: Scandinavian journal of clinical and laboratory investigation

Published: June 13, 2015